Seven Grand Managers LLC Invests $1.25 Million in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Seven Grand Managers LLC opened a new position in Centessa Pharmaceuticals, buying 50,000 shares worth about $1.25 million in the fourth quarter.
• Centessa’s stock has been volatile but recently traded near its 52-week high, opening at $39.77 versus a high of $40.26, with the company now valued at about $5.93 billion.
• The company reported a wider-than-expected loss in its latest quarterly results, and analysts currently have a Hold consensus rating on the stock despite an average price target of $41.33.

Seven Grand Managers LLC purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 50,000 shares of the company's stock, valued at approximately $1,250,000.

Several other institutional investors also recently modified their holdings of CNTA. Millennium Management LLC grew its position in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company's stock worth $8,760,000 after buying an additional 210,737 shares during the period. Jane Street Group LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $2,176,000. Geode Capital Management LLC grew its position in shares of Centessa Pharmaceuticals by 44.7% during the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company's stock worth $1,149,000 after buying an additional 26,994 shares during the period. JPMorgan Chase & Co. grew its position in shares of Centessa Pharmaceuticals by 155.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company's stock worth $5,630,000 after buying an additional 260,702 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Centessa Pharmaceuticals by 29.2% during the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company's stock worth $1,291,000 after buying an additional 22,205 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $39.77 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $10.95 and a twelve month high of $40.26. The firm's 50 day moving average price is $37.31 and its two-hundred day moving average price is $29.75. The firm has a market cap of $5.93 billion, a P/E ratio of -22.22 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.14). On average, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 309,112 shares of company stock worth $8,424,535. Insiders own 4.09% of the company's stock.

Analysts Set New Price Targets

CNTA has been the subject of several analyst reports. Lifesci Capital cut shares of Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Truist Financial lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating and set a $38.00 price objective on the stock. in a research note on Monday, April 13th. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, March 31st. Finally, Guggenheim lowered shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.